Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fb7bdbc12cec44a1e8f3e636ee23564 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 |
filingDate |
2022-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf9fb52b84fa1b7c66b4c5b5ee02ca86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d1e5d78ea477ab63aaac7b486ca9d05 |
publicationDate |
2023-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2023029174-A1 |
titleOfInvention |
Pharmaceutical composition |
abstract |
A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises a drug component consisting of a) mometasone, mometasone furoate, or a combination thereof and b) formoterol fumarate dihydrate. The chemically stable pharmaceutical composition further comprises a propellant component comprising at least 90 weight % 1,1-difluoroethane (R-152a), and ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. The drug component is the sole drug component in the pharmaceutical composition. The chemically stable pharmaceutical composition is free of acid stabilizers. The chemically stable pharmaceutical composition is surfactant-free. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021244688-A1 |
priorityDate |
2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |